Drug intelligence / Profile preview

allos-1000

Development stage: Unknown
Lead developer: Ensol Biosciences
Modality: Peptides

Overview

Allos-1000 is a synthetic peptide drug developed by Ensol Biosciences. It is being investigated primarily for the treatment of immune system diseases, congenital disorders, and skin and musculoskeletal diseases. Its main active indication in clinical development is atopic dermatitis. The drug's mechanism of action and specific molecular targets have not been publicly disclosed as of the latest available data. As of May 2025, its highest global R&D status is Phase 1 clinical trials[1].

Other names: ALLOS1000ALLOS-1000ALLOS 1000

Beyond the preview

Go deeper on allos-1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allos-1000.

Explore the full profile